The 2021 novelties in prognostic and therapeutic tissue markers in patients with prostate cancer (PCa) can be subdivided into two major groups. The first group is related to prognostic markers based on morphological and immunohistochemical evaluations. The novelties in this group can then be subdivided into two subgroups, one involving morphologic evaluation only, i.e., PCa grading, and the other involving both morphologic and immunohistochemical evaluations, i.e., aggressive variant PCa (AVPCa). Grading concerns androgen-dependent PCa, while AVPCa represents a late phase in its natural history, when it becomes androgen-independent. The novelties of the other major group are related to molecular markers predicting significant disease or response to therapy. This group mainly includes novelties in the molecular evaluation of PCa in tissue material and liquid biopsies.

Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation / Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Massari F.; Santoni M.; Scarpelli M.; Cheng L.; Montironi R.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:14(2021), pp. 3471.1-3471.12. [10.3390/cancers13143471]

Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation

Massari F.;
2021

Abstract

The 2021 novelties in prognostic and therapeutic tissue markers in patients with prostate cancer (PCa) can be subdivided into two major groups. The first group is related to prognostic markers based on morphological and immunohistochemical evaluations. The novelties in this group can then be subdivided into two subgroups, one involving morphologic evaluation only, i.e., PCa grading, and the other involving both morphologic and immunohistochemical evaluations, i.e., aggressive variant PCa (AVPCa). Grading concerns androgen-dependent PCa, while AVPCa represents a late phase in its natural history, when it becomes androgen-independent. The novelties of the other major group are related to molecular markers predicting significant disease or response to therapy. This group mainly includes novelties in the molecular evaluation of PCa in tissue material and liquid biopsies.
2021
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation / Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Massari F.; Santoni M.; Scarpelli M.; Cheng L.; Montironi R.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:14(2021), pp. 3471.1-3471.12. [10.3390/cancers13143471]
Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Massari F.; Santoni M.; Scarpelli M.; Cheng L.; Montironi R.
File in questo prodotto:
File Dimensione Formato  
Cancers 2021 [PCa2021].pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 8.62 MB
Formato Adobe PDF
8.62 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/908582
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact